At a median follow-up of 53 months, the median PFS was not reached with KRd and was 48.8 months with VRd. Carfilzomib, lenalidomide, and dexamethasone (KRd) significantly prolonged progression-free ...

The acquisition of two Chicago-based firms creates a new market for Aprio, reinforces commitment to expanding its position across the U.S. "We are pleased to expand our footprint into the greater ...

KRd showed superior PFS and deeper responses compared to VRd in newly diagnosed multiple myeloma patients, achieving higher complete response and MRD-negativity rates. The trial demonstrated ...

“Patients did great” with a four-drug regimen for multiple myeloma, an expert told CURE®. Patients with newly diagnosed multiple myeloma treated with the four-drug combination of Sarclisa (isatuximab) ...

E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma. Phase 3 randomized ...

Patients with newly diagnosed multiple myeloma often receive twice-weekly triplet regimens of carfilzomib, lenalidomide, and dexamethasone (KRd). New data suggest less frequent dosing can be equally ...

Clinical characteristics, survival outcomes, and prognostic factors in subcutaneous panniculitis like T-cell lymphoma: National Cancer Database analysis (2004-2018). This is an ASCO Meeting Abstract ...

RIO DE JANEIRO — A quadruplet induction regimen of isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in the treatment of newly diagnosed multiple myeloma (MM) shows a notably high ...

New real-world data confirms that carfilzomib, lenalidomide, and dexamethasone (KRd) are a safe and effective option for patients with relapsed or refractory multiple myeloma. A new analysis of the ...

In 2011, a group of experts in different fields like solar photovoltaics, renewable energies, business internationalization, and foreign investments, led by the co-founders: Sergio Cardamas and Oscar ...